Please help distribute. Treatment Action Group (TAG) @TAGHIVscience, in collaboration with #HIV i-Base and Project Inform, is requesting organizational and individual sign-ons to a letter urging Gilead Sciences to develop a stand-alone formulation of tenofovir alafenamide fumarate (TAF), an experimental prodrug of the nucleotide reverse transcriptase inhibitor tenofovir. We are concerned that Gilead’s current development plans, as we understand them, might limit TAF to a component of fixed-dose combinations (FDCs) only. Though this exemplifies Gilead’s leadership in manufacturing simplified and convenient innovator company antiretroviral (ARV) regimens, it overlooks the potential importance of a stand-alone TAF formulation for use in combination with a variety of non-Gilead agents—notably low-cost generic ARVs in low-, middle-, and high-income countries—and as a component of tailored regimens for treatment-experienced people living with HIV, including those with mutated strains conferring resistance to tenofovoir disoproxil fumarate (TDF).
Posted on: Thu, 13 Jun 2013 17:16:56 +0000